Hatteras’ mission is to create transformative healthcare companies in the research-driven, undercapitalized regions of the Southeast and Mid-Atlantic. Over half of our portfolio companies were created with our initial investment.

At Hatteras Venture Partners, we believe that breakthrough science and entrepreneurial innovation have the power to create valuable new ways of treating and diagnosing disease, providing value for our investors and transforming human health.

The Hatteras team brings operational experience, a renowned strategic partner network, and a successful investment track record. We are passionate about utilizing our backgrounds to engage entrepreneurs and enhance the value of their companies.

Portfolio

Latest News

G1 Therapeutics to Evaluate Trilaciclib (G1T28) in Combination with Immune Checkpoint Inhibitor in Small-Cell Lung Cancer

December 5, 2016

Phase 2 study evaluating potential of Genentech’s Tecentriq plus trilaciclib and chemotherapy as a first-line treatment for small-cell lung cancer patients expected to begin in first half of 2017  …

More News